Eye
Six biomarkers predict AMD progression with greater certainty than ‘large drusen’ sign
Researchers have identified biomarkers that predict age-related macular degeneration progression as well as biomarkers associated with progression to geographic atrophy and neovascularization, according to a review published in Ophthalmology Retina.
First patient dosed in second part of trial for AVD-104 to treat geographic atrophy
Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial investigating AVD-104 to treat geographic atrophy secondary to age-related macular degeneration.
Alcon launches Total30 Multifocal contact lenses in Canada
The Total30 Multifocal, a reusable, monthly lens for patients with presbyopia, is now available in Canada, manufacturer Alcon announced in a press release.
Researchers identify risk factors for myopic maculopathy progression in children
Worse best-corrected visual acuity, longer axial length, faster axial length elongation and severe myopic maculopathy were reported risk factors for myopic maculopathy progression in children, according to research in JAMA Ophthalmology.
Vision Council values optical industry at more than $65 billion in 2023
The Vision Council has released data valuing the optical market at $65.6 billion for 2023, indicating growth in the volume of eye exams and prescription eye care products sold.
AI system boosts diabetic eye exam completion rates among youth with diabetes
An autonomous artificial intelligence system increased diabetic eye exam completion rates in youth with diabetes and could help close the care gap in underserved communities, according to a study published in Nature Communications.
Aviceda reports positive topline data for AVD-104 in patients with geographic atrophy
Aviceda Therapeutics announced positive safety and efficacy outcomes from part 1 of its phase 2/3 SIGLEC trial for AVD-104, which is being evaluated in patients with geographic atrophy secondary to age-related macular degeneration.
EUROLIGHT registry study to evaluate photobiomodulation in dry AMD
LumiThera announced the EUROLIGHT registry study will evaluate the safety, efficacy and biomarkers of photobiomodulation treatment for dry age-related macular degeneration.
Aviceda enrolls first patient in phase 2 trial of AVD-104 for diabetic macular edema
Aviceda Therapeutics has enrolled the first patient in its GLYCO phase 2 clinical trial studying AVD-104, an engineered glycan nanoparticle developed to treat diabetic macular edema.
Vision coverage abuses threaten eye care in US, AOA survey says
A survey conducted after the Jan. 4 American Optometric Association’s virtual townhall highlights optometrists’ concerns about anti-patient, anti-doctor and anti-competitive abuses in the vision plan industry.